The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

Omisirge® is a commercialized mismatched ... modified allogeneic hematopoietic progenitor cell therapy that was FDA approved and launched in 2023. It is the intent of the two companies that ...

For example, in April 2023, Gamida Cell Ltd. received FDA approval for Omisirge for adult and pediatric patients (aged 12 and older) undergoing cord blood transplantation after myeloablative ...

Silicon Labs , the leading innovator in low-power wireless, today reaffirmed its guidance for the first quarter of 2025 in conjunction with its 2025 Analyst Day. The company expects first-quarter ...

Iridium Communications Inc. , a leading provider of global voice and data satellite communications is proud to announce that Heimdall Power, an innovative leader in grid optimization, has adopted ...

With an FDA approved asset under its belt ... Gamida Cell is now marketing Omisirge, a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord blood.

Advanced cell therapies, such as Gamida Cell’s Omisirge, approved by the FDA in 2023 for hematologic malignancies, underscores the increasing significance of stem cell-based therapies. With ...